News

Yesterday, the ADAPT SMART infographic and the European Lead Factory animation won the best Innovative Medicines Initiative (IMI) Communication Product Awards. The awards were handed out as part of IMI’s 10th anniversary during the IMI Scientific Symposium in Brussels.

New program under Commit2Data umbrella will exist of 4-6 public private research projects, focusing on development of new approaches of prevention and early detection of cardiovascular disease.

As we are expanding our project portfolio, we are looking for a Program Manager Data Infrastructure.

The Japanese Global Health Innovative Technology Fund (GHIT) announced today that is investing approximately 76 million yen (US$0.7 million) in a partnership involving Japan’s Institute of Tropical Medicine, Nagasaki University (NEKKEN) and the Netherlands-based Lygature and Leiden University Medical Center (LUMC).

As we are expanding our project portfolio, we are looking for a Legal & Business Development manager.

The Dutch life sciences sector has produced a bidbook to attract foreign investor, companies and researchers.

As we are expanding our project portfolio, we will be hiring two entry-level Program Managers.

Yesterday, H.M. Queen Máxima officially launched Oncode Institute! 43 excellent cancer research groups in the Netherlands will work together in Oncode Institute to bring fundamental insights into a clinical setting to improve patient outcomes. As Lygature, we are proud to work as a partner in Oncode Institute to support excellent research.

On January 16, 2018, the U.S. Government Accountability Office (GAO) released a report that examines the challenges of reviewing generic versions of nonbiological complex drugs (NBCDs). The report underlines the scientific challenges involved when demonstrating equivalence between brand and generic NBCDs.

Meta Roestenberg, physician-scientist at the Parasitology Department of Leiden University Medical Center (LUMC), talks about an innovative approach to testing vaccines and drugs for poverty-related diseases such as malaria.

Schistosomiasis is one of the most prevalent parasitic diseases worldwide, and a very important one in terms of public health burden and economic impact. The Pediatric Praziquantel Consortium aims to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children.

The company Aduro Biotech announces the initiation of a Phase 1/2 clinical trial of BION-1301, an anti-APRIL antibody, for the treatment of multiple myeloma

Lygature wishes you a wonderful holiday season and an innovative New Year sparked by inspiration and collaboration.

The European & Developing Countries Clinical Trials Partnership (EDCTP) and the Japanese Global Health Innovative Technology Fund (GHIT) announced a new partnership today, 8 December 2017, to support product development research.